{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T08:39:02Z","timestamp":1794645542153,"version":"4.9.1"},"reference-count":105,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ygyno.2020.10.043","type":"journal-article","created":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T19:01:57Z","timestamp":1604948517000},"page":"586-601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":121,"title":["Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity"],"prefix":"10.1016","volume":"160","author":[{"given":"Shinya","family":"Matsuzaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Klar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Matsuzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda D.","family":"Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2020.10.043_bb0005","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ygyno.2015.03.041","article-title":"Uterine carcinosarcoma: a review of the literature","volume":"137","author":"Cantrell","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0010","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1038\/modpathol.2011.88","article-title":"Molecular markers and clinical behavior of uterine carcinosarcomas: focus on the epithelial tumor component","volume":"24","author":"de Jong","year":"2011","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11070964","article-title":"Molecular basis of tumor heterogeneity in endometrial carcinosarcoma","volume":"11","author":"Leskela","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0020","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1038\/s41467-019-12985-x","article-title":"Clinically relevant molecular subtypes and genomic alteration-independent differentiation in gynecologic carcinosarcoma","volume":"10","author":"Gotoh","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0025","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ccell.2017.02.010","article-title":"Integrated molecular characterization of uterine carcinosarcoma","volume":"31","author":"Cherniack","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0030","doi-asserted-by":"crossref","first-page":"12238","DOI":"10.1073\/pnas.1614120113","article-title":"Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition","volume":"113","author":"Zhao","year":"2016","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0035","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1097\/IGC.0000000000000228","article-title":"Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma","volume":"24","author":"Berton-Rigaud","year":"2014","journal-title":"International journal of gynecological cancer"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0040","author":"National Cancer Institute's The Surveillance, Epidemiology, and End Results (SEER) Program"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0045","article-title":"Trends of uterine carcinosarcoma in the United States","volume":"29","author":"Matsuo","year":"2018","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0050","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/cncr.11484","article-title":"Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus","volume":"98","author":"Sherman","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0055","unstructured":"Uterine Neoplasm. NCCN Guidelines Version 1.2020. National Comprehensive Cancer Network. https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx (accessed 7\/28\/2020)."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0060","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ygyno.2017.03.017","article-title":"Surgical-pathological findings in type 1 and 2 endometrial cancer: an NRG oncology\/gynecologic oncology group study on GOG-210 protocol","volume":"145","author":"Creasman","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0065","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ygyno.2015.08.014","article-title":"Patterns of care, predictors and outcomes of chemotherapy for uterine carcinosarcoma: a National Cancer Database analysis","volume":"139","author":"Rauh-Hain","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0070","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ygyno.2016.12.012","article-title":"Extent of pelvic lymphadenectomy and use of adjuvant vaginal brachytherapy for early-stage endometrial cancer","volume":"144","author":"Matsuo","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0075","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0090-8258(83)90111-7","article-title":"Two pathogenetic types of endometrial carcinoma","volume":"15","author":"Bokhman","year":"1983","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0080","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(15)00130-0","article-title":"Endometrial cancer","volume":"387","author":"Morice","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0085","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41379-019-0358-x","article-title":"HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy","volume":"33","author":"Rottmann","year":"2020","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0090","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/modpathol.2013.113","article-title":"Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice","volume":"26","author":"Buza","year":"2013","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0095","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0100","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ygyno.2019.08.019","article-title":"TCGA molecular groups of endometrial cancer: pooled data about prognosis","volume":"155","author":"Raffone","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0105","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41568-019-0177-x","article-title":"Clinical actionability of molecular targets in endometrial cancer","volume":"19","author":"Urick","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0110","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/ijgc-2019-000920","article-title":"Molecular variations in uterine carcinosarcomas identify therapeutic opportunities","volume":"30","author":"Crane","year":"2020","journal-title":"International journal of gynecological cancer"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0115","doi-asserted-by":"crossref","first-page":"25880","DOI":"10.1073\/pnas.1911310116","article-title":"Fbxw7 is a driver of uterine carcinosarcoma by promoting epithelial-mesenchymal transition","volume":"116","author":"Cuevas","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0120","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1002\/1097-0142(20000615)88:12<2782::AID-CNCR17>3.0.CO;2-K","article-title":"Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus","volume":"88","author":"Yamada","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0125","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/annonc\/mdw161","article-title":"Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma","volume":"27","author":"Matsuo","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0130","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.suronc.2018.05.017","article-title":"Characterizing sarcoma dominance pattern in uterine carcinosarcoma: Homologous versus heterologous element","volume":"27","author":"Matsuo","year":"2018","journal-title":"Surg Oncol"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0135","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1245\/s10434-018-6695-z","article-title":"Proposal for a risk-based categorization of uterine carcinosarcoma","volume":"25","author":"Matsuo","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0140","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1245\/s10434-018-6547-x","article-title":"Significance of lymphovascular space invasion by the sarcomatous component in uterine carcinosarcoma","volume":"25","author":"Matsuo","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0145","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ygyno.2020.07.010","article-title":"Malignant peritoneal cytology and increased mortality risk in stage I non-endometrioid endometrial cancer","volume":"159","author":"Matsuo","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0150","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ygyno.2017.11.036","article-title":"Significance of venous thromboembolism in women with uterine carcinosarcoma","volume":"148","author":"Matsuo","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0155","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.ygyno.2016.10.016","article-title":"Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: an NRG oncology\/gynecologic oncology group ancillary analysis","volume":"143","author":"Fader","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0160","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ygyno.2014.07.097","article-title":"Comparison of outcomes in early stage uterine carcinosarcoma and uterine serous carcinoma","volume":"135","author":"Desai","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0165","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ejca.2020.04.012","article-title":"Impact of different adjuvant treatment approaches on survival in stage III endometrial cancer: A population-based study","volume":"133","author":"van Weelden","year":"2020","journal-title":"European journal of cancer"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0170","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ygyno.2017.02.001","article-title":"Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma","volume":"145","author":"Matsuo","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0175","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ygyno.2017.01.010","article-title":"Stage I uterine carcinosarcoma: matched cohort analyses for lymphadenectomy, chemotherapy, and brachytherapy","volume":"145","author":"Seagle","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0180","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ygyno.2017.10.008","article-title":"Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma","volume":"147","author":"Matsuo","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0185","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1245\/s10434-015-4612-2","article-title":"Survival of patients with uterine carcinosarcoma undergoing sentinel lymph node mapping","volume":"23","author":"Schiavone","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0190","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ygyno.2016.04.004","article-title":"Optimal cytoreductive surgery in patients with advanced uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese gynecologic oncology group","volume":"141","author":"Harano","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0195","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ygyno.2020.06.003","article-title":"Sentinel lymph node biopsy versus lymphadenectomy for high-grade endometrial cancer staging (SENTOR trial): a prospective multicenter cohort study","volume":"159","author":"Cusimano","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0200","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1200\/JCO.2006.06.4907","article-title":"Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a gynecologic oncology group study","volume":"25","author":"Homesley","year":"2007","journal-title":"Journal of clinical oncology"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0205","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1006\/gyno.2000.6001","article-title":"A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a gynecologic oncology group study","volume":"79","author":"Sutton","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0210","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1200\/JCO.2009.26.8326","article-title":"Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study","volume":"28","author":"Powell","year":"2010","journal-title":"Journal of clinical oncology"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0215","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1200\/JCO.2019.37.15_suppl.5500","article-title":"A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: an NRG oncology trial","volume":"37","author":"Powell","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0220","first-page":"271","article-title":"Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a gynecologic oncology group study","volume":"70","author":"Thigpen","year":"1986","journal-title":"Cancer treatment reports"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0225","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1006\/gyno.2001.6256","article-title":"Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study","volume":"83","author":"Curtin","year":"2001","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0230","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ygyno.2004.09.045","article-title":"Expression of c-kit in uterine carcinosarcoma","volume":"96","author":"Menczer","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0235","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18051100","article-title":"Target therapies for uterine carcinosarcomas: current evidence and future perspectives","volume":"18","author":"Vitale","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0240","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ygyno.2005.07.124","article-title":"EGFR expression and HER2\/neu overexpression\/amplification in endometrial carcinosarcoma","volume":"100","author":"Livasy","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0245","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ygyno.2004.08.042","article-title":"Localization of the VEGF and angiopoietin genes in uterine carcinosarcoma","volume":"95","author":"Emoto","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0250","first-page":"309","article-title":"Novel targeted therapies in ovarian and uterine carcinosarcomas","volume":"25","author":"Han","year":"2018","journal-title":"Discov. Med."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0255","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/cncr.32677","article-title":"Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway","volume":"126","author":"Rubinstein","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0260","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.1158\/1078-0432.CCR-16-2862","article-title":"SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2\/Neu expression","volume":"23","author":"Menderes","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0265","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"Journal of clinical oncology"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0270","article-title":"The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas","author":"Moukarzel","year":"2020","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0275","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21020556","article-title":"Possibilities of improving the clinical value of immune checkpoint inhibitor therapies in cancer care by optimizing patient selection","volume":"21","author":"Iivanainen","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0280","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1200\/JCO.2017.74.5471","article-title":"Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial","volume":"35","author":"Frenel","year":"2017","journal-title":"Journal of clinical oncology"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0285","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ygyno.2019.11.035","article-title":"Immune checkpoint expression, microsatellite instability, and mutational burden: identifying immune biomarker phenotypes in uterine cancer","volume":"156","author":"Jones","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0290","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0295","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ygyno.2020.01.020","article-title":"High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer","volume":"157","author":"Engerud","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0300","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.19.02627","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer","volume":"38","author":"Makker","year":"2020","journal-title":"Journal of clinical oncology"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0305","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1200\/EDBK_280503","article-title":"A review of immune checkpoint blockade therapy in endometrial cancer","author":"Green","year":"2020","journal-title":"American Society of Clinical Oncology Educational Book"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0310","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.addr.2017.04.010","article-title":"Progress in tumor-associated macrophage (TAM)-targeted therapeutics","volume":"114","author":"Ngambenjawong","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0315","doi-asserted-by":"crossref","first-page":"929","DOI":"10.2217\/fon-2018-0745","article-title":"Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale","volume":"15","author":"Grunwald","year":"2019","journal-title":"Future Oncol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0320","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212513","article-title":"Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway","volume":"14","author":"Kato","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0325","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ygyno.2015.05.019","article-title":"Significance of monocyte counts on tumor characteristics and survival outcome of women with endometrial cancer","volume":"138","author":"Matsuo","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0330","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.cell.2006.01.007","article-title":"Macrophages: obligate partners for tumor cell migration, invasion, and metastasis","volume":"124","author":"Condeelis","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0335","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/s13046-018-0981-2","article-title":"The epithelial-to-mesenchymal transition induced by tumor-associated macrophages confers chemoresistance in peritoneally disseminated pancreatic cancer","volume":"37","author":"Kuwada","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0340","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","article-title":"Tumor-associated macrophages: from mechanisms to therapy","volume":"41","author":"Noy","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0345","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/icb.2013.38","article-title":"Inactivation of tumor-specific CD8(+) CTLs by tumor-infiltrating tolerogenic dendritic cells","volume":"91","author":"Harimoto","year":"2013","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0350","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","article-title":"New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer","volume":"20","author":"Dongre","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0355","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nrc3447","article-title":"Regulatory networks defining EMT during cancer initiation and progression","volume":"13","author":"De Craene","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0360","doi-asserted-by":"crossref","first-page":"re8","DOI":"10.1126\/scisignal.2005189","article-title":"Signaling mechanisms of the epithelial-mesenchymal transition","volume":"7","author":"Gonzalez","year":"2014","journal-title":"Sci Signal"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0365","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1158\/0008-5472.CAN-15-0287","article-title":"Network-based approaches to understand the roles of miR-200 and other microRNAs in cancer","volume":"75","author":"Bracken","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0370","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/path.4289","article-title":"A core microRNA signature associated with inducers of the epithelial-to-mesenchymal transition","volume":"232","author":"Diaz-Martin","year":"2014","journal-title":"J. Pathol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0375","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.humpath.2012.05.013","article-title":"Molecular events in endometrial carcinosarcomas and the role of high mobility group AT-hook 2 in endometrial carcinogenesis","volume":"44","author":"Romero-Perez","year":"2013","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0380","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/path.2802","article-title":"Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma","volume":"223","author":"Castilla","year":"2011","journal-title":"J. Pathol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0385","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.2353\/ajpath.2009.081018","article-title":"Requirement of the Akt\/beta-catenin pathway for uterine carcinosarcoma genesis, modulating E-cadherin expression through the transactivation of slug","volume":"174","author":"Saegusa","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0395","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev-med-121211-091527","article-title":"Cytokines, obesity, and cancer: new insights on mechanisms linking obesity to cancer risk and progression","volume":"64","author":"Gilbert","year":"2013","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0400","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1006\/gyno.1998.4941","article-title":"Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumors","volume":"69","author":"Zelmanowicz","year":"1998","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0405","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nrc.2017.118","article-title":"EMT in cancer","volume":"18","author":"Brabletz","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0410","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1101\/gad.1640608","article-title":"The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2","volume":"22","author":"Park","year":"2008","journal-title":"Genes Dev."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0415","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/ncb1722","article-title":"The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1","volume":"10","author":"Gregory","year":"2008","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0420","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.rbmo.2015.12.013","article-title":"microRNA miR-200b affects proliferation, invasiveness and stemness of endometriotic cells by targeting ZEB1, ZEB2 and KLF4","volume":"32","author":"Eggers","year":"2016","journal-title":"Reprod. BioMed. Online"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0425","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12010025","article-title":"Nanomaterials as inhibitors of epithelial mesenchymal transition in cancer treatment","volume":"12","author":"Cordani","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0430","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/s41416-018-0246-z","article-title":"Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer","volume":"119","author":"Melisi","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0435","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000056","article-title":"A phase 2 study of galunisertib (TGF-beta1 receptor type I inhibitor) and sorafenib in patients with advanced hepatocellular carcinoma","volume":"10","author":"Kelley","year":"2019","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0440","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00280-019-03931-1","article-title":"Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor-beta inhibitor galunisertib in patients with pancreatic cancer","volume":"84","author":"Gueorguieva","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0445","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1007\/s10637-020-00910-9","article-title":"Phase 1b\/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma","volume":"38","author":"Wick","year":"2020","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0450","article-title":"CD70 antibody-drug conjugate as a potential therapeutic agent for uterine leiomyosarcoma","author":"Nakae","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0455","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11060838","article-title":"The role of epithelial-to-mesenchymal plasticity in ovarian cancer progression and therapy resistance","volume":"11","author":"Loret","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0460","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2008.07.001","article-title":"TGFbeta in cancer","volume":"134","author":"Massague","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0465","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.trecan.2016.11.008","article-title":"Targeting TGF-beta signaling in cancer","volume":"3","author":"Colak","year":"2017","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0470","series-title":"Akhurst RJ","author":"Derynck","year":"2020"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0475","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1257453","article-title":"Novel TGF-beta inhibitors ready for prime time in onco-immunology","volume":"6","author":"de Gramont","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0480","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pharmthera.2014.11.001","article-title":"Targeting the TGFbeta pathway for cancer therapy","volume":"147","author":"Neuzillet","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0485","doi-asserted-by":"crossref","first-page":"14646","DOI":"10.18632\/oncotarget.3711","article-title":"Role of TGF-beta signaling in uterine carcinosarcoma","volume":"6","author":"Dwivedi","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0490","doi-asserted-by":"crossref","DOI":"10.1038\/nutd.2012.1","article-title":"Getting \u2018Smad\u2019 about obesity and diabetes","volume":"2","author":"Tan","year":"2012","journal-title":"Nutr Diabetes"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0495","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.cmet.2011.04.013","article-title":"Protection from obesity and diabetes by blockade of TGF-beta\/Smad3 signaling","volume":"14","author":"Yadav","year":"2011","journal-title":"Cell Metab."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0500","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1056\/NEJMsa1909301","article-title":"State-level prevalence of adult obesity and severe obesity","volume":"381","author":"Ward","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0505","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/ijc.30537","article-title":"Distinct molecular landscapes between endometrioid and nonendometrioid uterine carcinomas","volume":"140","author":"Jones","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2020.10.043_bb0510","first-page":"177","article-title":"p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis","volume":"150","author":"Tashiro","year":"1997","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0515","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1093\/jnci\/djs345","article-title":"Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses","volume":"104","author":"Kuhn","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0520","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/ng.2455","article-title":"Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes","volume":"44","author":"Le Gallo","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0525","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/modpathol.2013.107","article-title":"Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles","volume":"27","author":"McConechy","year":"2014","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2020.10.043_bb0530","doi-asserted-by":"crossref","first-page":"5939","DOI":"10.1158\/1078-0432.CCR-18-0412","article-title":"Clinical utility of prospective molecular characterization in advanced endometrial cancer","volume":"24","author":"Soumerai","year":"2018","journal-title":"Clin Cancer Res"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820340658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820340658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:53:56Z","timestamp":1758772436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820340658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":105,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0090825820340658"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.10.043","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.10.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}